Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Dig Dis Sci. 2009 Oct;54(10):2207-14. doi: 10.1007/s10620-008-0609-z. Epub 2008 Dec 5.

Patient preferences for the chemoprevention of colorectal cancer.

Author information

  • 1Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA. chur@mgh-ita.org

Abstract

Although evidence suggests that aspirin and celecoxib may reduce the risk of colorectal cancer (CRC), these drugs can also cause harmful side effects. The aim of this study was to characterize patient preferences for celecoxib and aspirin. Participants completed a computer-based patient decision-making questionnaire that included an educational component outlining the benefits and harms of celecoxib and aspirin. Under the base conditions 7.4% would take celecoxib and 43.6% would take aspirin; males were more willing than females to take aspirin. Patients identified the increased risk of myocardial infarction and gastrointestinal events as the primary reasons for their unwillingness to take celecoxib and aspirin, respectively. A majority of subjects would not take either drug, after considering their benefits and harms, although participants were almost six times more likely to take aspirin than celecoxib. These data serve to inform physicians and researchers regarding the variability and factors that affect patient preferences for CRC chemoprevention.

PMID:
19057995
[PubMed - indexed for MEDLINE]
PMCID:
PMC3737565
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Write to the Help Desk